A study of hydroxychloroquine published in The Lancet has been withdrawn

The three authors retracted their paper in The Lancet on the use of hydroxychloroquine to treat Covid-19. An antimalarial drug touted by U.S. President Donald Trump to treat the new crown has been linked to an increased risk of death and heart disease, according to a report.

A study of hydroxychloroquine published in The Lancet has been withdrawn

The study, published Friday in the medical journal The Lancet, found that neither hydroxychloroquine nor chloroquine could benefit new crown patients, either alone or in combination with antibiotics.

The study looked at the records of 15,000 patients who had received one of these antimalarial drugs and one of two antibiotics that were sometimes combined. Regardless of how the four drugs were combined, the risk of death was higher than that of 81,000 patients who did not use the drugs.

The combination of hydroxychloroquine and an antibiotic led to the greatest increase in risk, with 8 percent of patients in the drug group experiencing arrhythmia and a control group of only 0.3 percent. The researchers say the drugs should only be used for research on coronavirus therapy, and will clearly show the impact of reliable research.

A study of hydroxychloroquine published in The Lancet has been withdrawn